Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term BRCA2. Found 13 abstracts

Petrucelli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genetics in Medicine. 2010 May;12(5):245-59.   PMCID: not NIH funded
Apicella C, Peacock SJ, Andrews L, Tucker K, Daly MB, Hopper JL. Measuring, and identifying predictors of, women's perceptions of three types of breast cancer risk: population risk, absolute risk and comparative risk. British Journal of Cancer. 2009 Feb;100(4):583-9.   PMCID: PMC2653735
Fang CY, Cherry C, Devarajan K, Li TY, Malick J, Daly MB. A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer. Gynecologic Oncology. 2009 Mar;112(3):594-600.   PMCID: PMC2697574
Bradbury AR, Ibe CN, Dignam JJ, Cummings SA, Verp M, White M, Artioli G, Dudlicek L, Olopade OL. Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genetics in Medicine. 2008 Mar;10(3):161-6.
Apicella C, Dowty JG, Dite GS, Jenkins MA, Senle RT, Daly MB, Andrulis IL, John EM, Buys SS, Li FP, Glendon G, Chung W, Ozcelik H, Miron A, Kotar K, Southey MC, Foulkes WD, Hopper JL. Validation study of the LAMBDA model for predicting the BRCA1 or BRCA2 mutation carrier status of North American Ashkenazi Jewish women. Clinical genetics. 2007 Aug;72(2):87-97.
Bane AL, Beck JC, Bleiweiss I, Buys SS, Catalano E, Daly MB, Giles G, Godwin AK, Hibshoosh H, Hopper JL, John EM, Layfield L, Longacre T, Miron A, Senie R, Southey MC, West DW, Whittemore AS, Wu H, Andrulis IL, O'Malley FP. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. American Journal of Surgical Pathology. 2007 Jan;31(1):121-8.
Apicella C, Peacock SJ, Andrews L, Tucker K, Bankier A, Daly MB, Hopper JL. Determinants of preferences for genetic counselling in Jewish women. FAMILIAL CANCER. 2006 Jan;5(2):159-67.
Cai KQ, Klein-Szanto A, Karthik D, Edelson M, Daly MB, Ozols RF, Lynch HT, Godwin AK, Xu XX. Age-dependent morphological alterations of human ovaries from populations with and without BRCA mutations. Gynecologic Oncology. 2006 Nov;103(2):719-28.
Chen XW, Truong TT, Weaver J, Bove BA, Cattie K, Armstrong BA, Daly MB, Godwin AK. Intronic alterations in BRCA1 and BRCA2: Effect on mRNA splicing fidelity and expression. HUMAN MUTATION. 2006 May;27(5):427-35.
Gronwald J, Tung N, Foulkes WD, Offit K, Gershoni R, Daly M, Kim-Sing C, Olsson H, Ainsworth P, Eisen A, Saal H, Friedman E, Olopade O, Osborne M, Weitzel J, Lynch H, Ghadirian P, Lubinski J, Sun P, Narod SA. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. International journal of cancer. 2006 May;118(9):2281-4.
Kotsopoulos J, Lubinski J, Lynch HT, Neuhausen SL, Ghadirian P, Isaacs C, Weber B, Kim-Sing C, Foulkes WD, Gershoni-Baruch R, Ainsworth P, Friedman E, Daly M, Garber JE, Karlan B, Olopade OI, Tung N, Saal HM, Eisen A, Osborne M, Olsson H, Gilchrist D, Sun P, Narod SA. Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes & Control. 2005 Aug;16(6):667-74.
Whittemore AS, Balise RR, Pharoah PD, DiCioccio RA, Oakley-Girvan I, Ramus SJ, Daly M, Usinowicz MB, Garlinghouse-Jones K, Ponder BA, Buys S, Senie R, Andrulis I, John E, Hopper JL, Piver MS. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. British Journal of Cancer. 2004 Nov 29;91(11):1911-5.
Wang-Gohrke S, Weikel W, Risch H, Vesprini D, Abrahamson J, Lerman C, Godwin A, Moslehi R, Olipade O, Brunet JS, Stickeler E, Kieback DG, Kreienberg R, Weber B, Narod SA, Runnebaum IB. Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations. British Journal of Cancer. 1999 Sep;81(1):179-83.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term BRCA2

BRCA2 BRCA1 breast cancer susceptibility WOMEN OVARIAN-CANCER SURGICAL ADJUVANT BREAST ovarian population Oncology genetic counselling ovarian cancer ovarian-cancer breast-cancer Genetics & Heredity CARRIERS women Ashkenazi FAMILY-HISTORY germline mutations heterogeneity MENOPAUSE estrogen receptor RISK Screening NMD patient outcomes HORMONE REPLACEMENT THERAPY aberrant transcript cells DETERMINANTS SUSCEPTIBILITY GENES and morphological changes including ovarian tissues was examined mutations consultations BREAST-CANCER RISK prevention tamoxifen age at menarche brca1 FOLLOW-UP p53 genes ovulation carcinoma in-situ TUMOR CHARACTERISTICS PHENOTYPE splicing non-neoplastic diseases to determine if ovarian morphological changes Results No statistically significant difference in frequency of these noncarriers prophylactic salpingo-oophorectomy SURFACE reducing salpingo-oophorectomy PREVENTION with BRCA1 history BRCA2 genotypes or are Methods We assembled a panel of archived ovarian tissues: 52 ovarian risk especially inclusion cysts features-may associate with age or invaginations papillomatosis-inclusion cysts-and epithelial pre-malignant lesion tissue blocks were from prophylactic oophorectomies of a high-risk (HR) genetic Conclusions This study suggests that no significant increase in the increased risk presence of non-neoplastic ovarian morphological changes is associated UNITED-STATES SURGERY REDUCTION Quality of life GERMLINE MUTATIONS families etiological factor we have investigated a recent cancer precursors is controversial Here women age 45-54 of either HR or NR groups the frequency of these histological BRCA2 mutations Rather early-life SURVEILLANCE case-control study cancer sporadic breast-cancer information expression samples gene MICE TRIAL unknown susceptibility genes bilateral prophylactic oophorectomy colorectal-cancer stratification were assessed in a blinded fashion histolopathologic features was found between HR and NR groups However ABDOMINAL HYSTERECTOMY PROPHYLACTIC OOPHORECTOMY SPECIMENS communication hereditary breast and ovarian cancer SYMPTOMS inclusion cysts and deep invaginations were found much more commonly in breast PSYCHOLOGICAL DISTRESS surgical adjuvant biomarkers client preferences prophylactic oophorectomies PREVALENCE estrogen-receptor status reproductive modifiers decision-making 2 genotypes or reproductive history BREAST-CANCER PATIENTS variants of unknown significance CANCER-RISK 185DELAG nonsense founder mutations FAMILY REGISTRY family-history OVULATION COMMON BRCA1 dna-damage response germ-line mutations SURVIVAL TUMORIGENESIS reproductive factors MUTATIONS GONADOTROPINS AB Objective From analysis of pre-cancer ovarian tissues obtained from high familial risk Ovarian cancer ovaries from surgeries due to other non-ovarian-related cancer or MANAGEMENT prose-study-group tp53 ashkenazi-jewish individuals polymorphism oophorectomy mutation carriers ovarian cancer oral contraceptives PROPHYLACTIC OOPHORECTOMY several studies reported the increased prophylactic oophorectomies cancer (c) 2006 Elsevier Inc All rights reserved IMMUNOHISTOCHEMICAL MARKERS pathology collection of ovaries from prophylactic oophorectomies and control EARLY-STAGE satisfaction aging epithelium nonsense-mediated mRNA decay
Last updated on Thursday, April 02, 2020